Crinetics Pharmaceuticals announced it will report Q4 and full year 2025 financial results on February 26, 2026, with a management conference call at 4:30 p.m. ET. The company also recently initiated a Phase 2/3 pediatric trial for atumelnant in congenital adrenal hyperplasia and announced January 2026 inducement grants.

Crinetics Pharmaceuticals announced a conference call scheduled for January 5, 2026 to provide a commercialization update on PALSONIFY (paltusotine) and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. The company's lead product PALSONIFY is the first once-daily oral treatment approved by the FDA for acromegaly, while atumelnant is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.

Crinetics Pharmaceuticals initiated a Phase 1/2 clinical trial for CRN09682, an investigational nonpeptide drug conjugate targeting somatostatin receptor type 2-positive neuroendocrine tumors, marking a significant milestone in developing a potentially more precise targeted therapy.

Crinetics Pharmaceuticals reported Q3 earnings with lower-than-expected revenue and increased net losses, despite receiving FDA approval for its acromegaly treatment Palsonify and securing a licensing agreement with Sanwa Kagaku Kenkyusho.

Crinetics Pharmaceuticals granted stock options and restricted stock units to 20 new non-executive employees under its 2021 Employment Inducement Incentive Award Plan, with options and RSUs vesting over four years.

Crinetics Pharmaceuticals received FDA approval for Palsonify, its first once-daily oral treatment for acromegaly, potentially generating $800 million to $1.5 billion in peak sales. However, commercial execution risks and limited patient pool create uncertainty about the drug's market success.

Multiple stocks saw significant gains on Friday, with Crinetics Pharmaceuticals leading the pack after FDA approval, while other companies like BlackBerry, Perpetua Resources, and Scholar Rock also experienced notable stock price increases.

Multiple healthcare stocks experienced significant pre-market price movements, with some companies seeing notable gains while others faced declines.

Crinetics Pharmaceuticals presented long-term clinical data on PALSONIFY, an oral medication for acromegaly, showing sustained IGF-1 level control and stable patient symptoms across two Phase 3 clinical trials.

Crinetics Pharmaceuticals announced that it will present new research on its investigational drugs paltusotine and atumelnant at the American Association of Clinical Endocrinology Annual Meeting 2025. The company also granted inducement grants to employees in May 2025.

Crinetics Pharmaceuticals, a clinical-stage pharmaceutical company, will report its fourth quarter and full-year 2024 financial results on February 27, 2025. The company will host a conference call to discuss the results and provide a business update.

Crinetics Pharmaceuticals announced positive results from a Phase 2 trial of its investigational drug atumelnant for the treatment of congenital adrenal hyperplasia (CAH). The trial showed substantial and sustained reductions in key biomarkers and improvements in clinical signs and symptoms of CAH.